Depletion of FAPα-expressing cells by antibodies, FAP CAR-T cells and various FAP vaccines has been widely investigated in the treatment of cancer [45] and fibrosis [47, 48] and has shown safety and tolerability in phase I trials [49, 50]. This evidence concerns the gene FAP and cancer.